Wealth Effects LLC Lowers Stock Holdings in Altimmune, Inc. (NASDAQ:ALT)

Wealth Effects LLC reduced its position in Altimmune, Inc. (NASDAQ:ALT) by 6.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,850 shares of the company’s stock after selling 2,200 shares during the quarter. Wealth Effects LLC’s holdings in Altimmune were worth $237,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Dimensional Fund Advisors LP increased its holdings in Altimmune by 142.9% in the second quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company’s stock valued at $3,791,000 after buying an additional 335,444 shares during the last quarter. Bellevue Group AG boosted its position in shares of Altimmune by 43.9% during the 3rd quarter. Bellevue Group AG now owns 863,660 shares of the company’s stock worth $5,303,000 after acquiring an additional 263,660 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of Altimmune in the 3rd quarter valued at about $674,000. Exchange Traded Concepts LLC raised its position in shares of Altimmune by 74.4% during the 3rd quarter. Exchange Traded Concepts LLC now owns 216,761 shares of the company’s stock worth $1,331,000 after acquiring an additional 92,498 shares in the last quarter. Finally, Barclays PLC lifted its stake in Altimmune by 93.0% during the third quarter. Barclays PLC now owns 155,741 shares of the company’s stock worth $956,000 after purchasing an additional 75,064 shares during the last quarter. 78.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have recently weighed in on ALT. UBS Group initiated coverage on shares of Altimmune in a research report on Tuesday, November 12th. They set a “buy” rating and a $26.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of Altimmune in a research report on Wednesday, January 22nd. Finally, Stifel Nicolaus began coverage on Altimmune in a report on Wednesday, January 8th. They set a “buy” rating and a $18.00 price objective on the stock. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $20.83.

Altimmune Stock Down 1.0 %

Shares of NASDAQ:ALT opened at $6.93 on Wednesday. The company has a market cap of $492.86 million, a P/E ratio of -4.47 and a beta of 0.22. The business has a fifty day simple moving average of $7.87 and a 200-day simple moving average of $7.19. Altimmune, Inc. has a 52 week low of $5.28 and a 52 week high of $14.84.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.03. The company had revenue of $0.01 million for the quarter. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. During the same period in the prior year, the business earned ($0.39) EPS. Sell-side analysts expect that Altimmune, Inc. will post -1.35 earnings per share for the current fiscal year.

Altimmune Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.